Pacific Biosciences of California, Inc. (PACB)
NASDAQ: PACB · Real-Time Price · USD
1.700
-0.040 (-2.30%)
Apr 21, 2026, 1:53 PM EDT - Market open
PACB Revenue
In the year 2025, Pacific Biosciences of California had annual revenue of $160.01M with 3.89% growth. Pacific Biosciences of California had revenue of $44.65M in the quarter ending December 31, 2025, with 13.82% growth.
Revenue (ttm)
$160.01M
Revenue Growth
+3.89%
P/S Ratio
3.20
Revenue / Employee
$329,907
Employees
485
Market Cap
513.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 160.01M | 5.99M | 3.89% |
| Dec 31, 2024 | 154.01M | -46.51M | -23.19% |
| Dec 31, 2023 | 200.52M | 72.22M | 56.29% |
| Dec 31, 2022 | 128.30M | -2.21M | -1.69% |
| Dec 31, 2021 | 130.51M | 51.62M | 65.43% |
| Dec 31, 2020 | 78.89M | -12.00M | -13.20% |
| Dec 31, 2019 | 90.89M | 12.27M | 15.60% |
| Dec 31, 2018 | 78.63M | -14.84M | -15.88% |
| Dec 31, 2017 | 93.47M | 2.75M | 3.04% |
| Dec 31, 2016 | 90.71M | -2.07M | -2.23% |
| Dec 31, 2015 | 92.78M | 32.19M | 53.12% |
| Dec 31, 2014 | 60.59M | 32.41M | 115.02% |
| Dec 31, 2013 | 28.18M | 2.20M | 8.46% |
| Dec 31, 2012 | 25.98M | -7.88M | -23.27% |
| Dec 31, 2011 | 33.86M | 32.19M | 1,922.88% |
| Dec 31, 2010 | 1.67M | 1.54M | 1,140.00% |
| Dec 31, 2009 | 135.00K | -766.00K | -85.02% |
| Dec 31, 2008 | 901.00K | -1.26M | -58.34% |
| Dec 31, 2007 | 2.16M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Varex Imaging | 854.40M |
| Orthofix Medical | 822.31M |
| Tactile Systems Technology | 329.52M |
| OrthoPediatrics | 236.35M |
| Cerus | 206.13M |
| Cytek Biosciences | 201.49M |
| SI-BONE | 200.93M |
| Beta Bionics | 100.25M |
PACB News
- 4 hours ago - PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing - GlobeNewsWire
- 4 days ago - PacBio to Report First Quarter 2026 Financial Results on May 7, 2026 - GlobeNewsWire
- 6 days ago - PacBio and Covaris Announce Joint Workflow Enabling HiFi Long-Read Sequencing of FFPE Tumor Samples - GlobeNewsWire
- 4 weeks ago - Basecamp Research Selects PacBio HiFi Sequencing to Power Trillion Gene Atlas Initiative - GlobeNewsWire
- 6 weeks ago - PacBio Announces the Appointment of Chris Gibson to the Board of Directors - GlobeNewsWire
- 2 months ago - PacBio and DNAstack Launch First Global Federated HiFi Whole Genome Dataset to Accelerate Rare Disease Research - GlobeNewsWire
- 2 months ago - PacBio to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - PacBio Completes Sale of Short-Read Sequencing Assets - GlobeNewsWire